共 181 条
[1]
Motzer R(2019)NCCN guidelines insights: kidney Cancer, version 2.2020 J Natl Compr Cancer Netw 17 1278-1285
[2]
Jonasch E(2018)Second-line treatment landscape for renal cell carcinoma: a comprehensive review Oncologist. 23 540-555
[3]
Michaelson M(2019)Clinical efficacy and complication rate of Sunitinib 2/1 versus 4/2 schedule for the treatment of metastatic renal cell Cancer: a systematic review and meta-analysis Clin Genitourin Cancer 17 319-331
[4]
Nandagopal L(2019)Treatment selection for first-line metastatic renal cell carcinoma in Australia: impact of new therapy options Asia Pac J Clin Oncol 15 3-10
[5]
Gore J(2006)Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence J Clin Oncol 24 3101-3106
[6]
George S(2014)Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group Asia Pac J Clin Oncol. 10 60-65
[7]
Tannir N(2018)Risk factors for locoregional relapse after radical nephrectomy Asia Pac J Clin Oncol. 14 192-197
[8]
Pal S(2017)Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas Pharmacol Res 120 116-132
[9]
Atkins M(2020)Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs Cancer Treat Rev 84 101966-3318
[10]
Chen C(2009)Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 3312-508